Douglas E Levy1,2, Elissa V Klinger3, Jeffrey A Linder2,3, Eric W Fleegler4,5, Nancy A Rigotti1,2, Elyse R Park1,6, Jennifer S Haas2,3,7. 1. Mongan Institute Health Policy Center and Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital, Boston, MA. 2. Department of Medicine, Harvard Medical School, Boston, MA. 3. Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 4. Division of Emergency Medicine, Boston Children's Hospital, Boston, MA. 5. Department of Pediatrics, Harvard Medical School, Boston, MA. 6. Department of Psychiatry, Harvard Medical School, Boston, MA. 7. Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA.
Abstract
INTRODUCTION: Project CLIQ (Community Link to Quit) was a proactive population-outreach strategy using an electronic health records-based smoker registry and interactive voice recognition technology to connect low- to moderate-income smokers with cessation counseling, medications, and social services. A randomized trial demonstrated that the program increased cessation. We evaluated the cost-effectiveness of CLIQ from a provider organization's perspective if implemented outside the trial framework. METHODS: We calculated the cost, cost per smoker, incremental cost per additional quit, and, secondarily, incremental cost per additional life year saved of the CLIQ system compared to usual care using data from a 2011-2013 randomized trial assessing the effectiveness of the CLIQ system. Sensitivity analyses considered economies of scale and initial versus ongoing costs. RESULTS: Over a 20-month period (the duration of the trial) the program cost US $283 027 (95% confidence interval [CI] $209 824-$389 072) more than usual care in a population of 8544 registry-identified smokers, 707 of whom participated in the program. The cost per smoker was $33 (95% CI 28-40), incremental cost per additional quit was $4137 (95% CI $2671-$8460), and incremental cost per additional life year saved was $7301 (95% CI $4545-$15 400). One-time costs constituted 28% of costs over 20 months. Ongoing costs were dominated by personnel costs (71% of ongoing costs). Sensitivity analyses showed sharp gains in cost-effectiveness as the number of identified smokers increased because of the large initial costs. CONCLUSIONS: The CLIQ system has favorable cost-effectiveness compared to other smoking cessation interventions. Cost-effectiveness will be greatest for health systems with high numbers of smokers and with the high smoker participation rates. IMPLICATIONS: Health information systems capable of establishing registries of patients who are smokers are becoming more prevalent. This economic analysis illustrates the cost implications for health care systems adopting a proactive tobacco treatment outreach strategy for low- and middle-income smokers. We find that under many circumstances, the CLIQ system has a favorable cost-per-quit compared to other population-based tobacco treatment strategies. The strategy could be widely disseminable if health systems leverage economies of scale.
INTRODUCTION: Project CLIQ (Community Link to Quit) was a proactive population-outreach strategy using an electronic health records-based smoker registry and interactive voice recognition technology to connect low- to moderate-income smokers with cessation counseling, medications, and social services. A randomized trial demonstrated that the program increased cessation. We evaluated the cost-effectiveness of CLIQ from a provider organization's perspective if implemented outside the trial framework. METHODS: We calculated the cost, cost per smoker, incremental cost per additional quit, and, secondarily, incremental cost per additional life year saved of the CLIQ system compared to usual care using data from a 2011-2013 randomized trial assessing the effectiveness of the CLIQ system. Sensitivity analyses considered economies of scale and initial versus ongoing costs. RESULTS: Over a 20-month period (the duration of the trial) the program cost US $283 027 (95% confidence interval [CI] $209 824-$389 072) more than usual care in a population of 8544 registry-identified smokers, 707 of whom participated in the program. The cost per smoker was $33 (95% CI 28-40), incremental cost per additional quit was $4137 (95% CI $2671-$8460), and incremental cost per additional life year saved was $7301 (95% CI $4545-$15 400). One-time costs constituted 28% of costs over 20 months. Ongoing costs were dominated by personnel costs (71% of ongoing costs). Sensitivity analyses showed sharp gains in cost-effectiveness as the number of identified smokers increased because of the large initial costs. CONCLUSIONS: The CLIQ system has favorable cost-effectiveness compared to other smoking cessation interventions. Cost-effectiveness will be greatest for health systems with high numbers of smokers and with the high smoker participation rates. IMPLICATIONS: Health information systems capable of establishing registries of patients who are smokers are becoming more prevalent. This economic analysis illustrates the cost implications for health care systems adopting a proactive tobacco treatment outreach strategy for low- and middle-income smokers. We find that under many circumstances, the CLIQ system has a favorable cost-per-quit compared to other population-based tobacco treatment strategies. The strategy could be widely disseminable if health systems leverage economies of scale.
Authors: Donna M Vallone; Jennifer C Duke; Jennifer Cullen; Kristen L McCausland; Jane A Allen Journal: Am J Public Health Date: 2010-12-16 Impact factor: 9.308
Authors: Talitha L Feenstra; Heleen H Hamberg-van Reenen; Rudolf T Hoogenveen; Maureen P M H Rutten-van Mölken Journal: Value Health Date: 2005 May-Jun Impact factor: 5.725
Authors: Jack F Hollis; Timothy A McAfee; Jeffrey L Fellows; Susan M Zbikowski; Michael Stark; Karen Riedlinger Journal: Tob Control Date: 2007-12 Impact factor: 7.552
Authors: K Michael Cummings; Andrew Hyland; Shannon Carlin-Menter; Martin C Mahoney; Jeffrey Willett; Harlan R Juster Journal: J Public Health Manag Pract Date: 2011 May-Jun
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Douglas E Levy; Susan Regan; Giselle K Perez; Alona Muzikansky; Emily R Friedman; Julia Rabin; Nancy A Rigotti; Jamie S Ostroff; Elyse R Park Journal: JAMA Netw Open Date: 2022-06-01
Authors: Eric W Tai; Gery P Guy; C Brooke Steele; S Jane Henley; Michael S Gallaway; Lisa C Richardson Journal: Am J Prev Med Date: 2018-02-01 Impact factor: 5.043
Authors: Jordan M Neil; Caylin Marotta; Irina Gonzalez; Yuchiao Chang; Douglas E Levy; Amy Wint; Kimberly Harris; Saif Hawari; Elise Noonan; Grace Styklunas; Sydney Crute; Sydney E Howard; Joanne Sheppard; Inga T Lennes; Francine Jacobson; Efren J Flores; Jennifer S Haas; Elyse R Park; Nancy A Rigotti Journal: Contemp Clin Trials Date: 2021-10-01 Impact factor: 2.226
Authors: Nicole L Nollen; Matthew S Mayo; Jarron M Saint Onge; Taneisha S Scheuermann; Lisa Sanderson Cox; David Chae; Eleanor Leavens; Jasjit S Ahluwalia Journal: Exp Clin Psychopharmacol Date: 2021-08-09 Impact factor: 3.492
Authors: Viengneesee Thao; John A Nyman; David B Nelson; Anne M Joseph; Barbara Clothier; Patrick J Hammett; Steven S Fu Journal: Addiction Date: 2019-09-04 Impact factor: 6.526
Authors: Olivier Drouin; Ryoko Sato; Jeremy E Drehmer; Emara Nabi-Burza; Bethany Hipple Walters; Jonathan P Winickoff; Douglas E Levy Journal: JAMA Netw Open Date: 2021-04-01